NEW YORK, July 28, 2026, 05:05 EDT
- U.S. regular markets were shut. Gossamer changed hands at around $0.2613 in premarket trading, roughly 31% higher than Monday’s closing price.
- The FDA regarded the statistical robustness and treatment scale of PROSERA as matters for review, rather than for the initial filing.
- Gossamer Bio’s initial June liquidity assets totaled approximately $57 million, exceeding the covenant minimum of $40 million.
Gossamer Bio, Inc. NASDAQ:GOSS surged 46.6% on Monday, boosted by FDA feedback backing a planned seralutinib submission in September. Shares finished at $0.1994. The rally continued premarket.
The FDA described PROSERA’s concerns related to statistical significance and treatment impact as review issues, rather than filing concerns. Gossamer intends to file its new drug application in September. If the application is accepted, a verdict could arrive in the third quarter of 2027.
This limits the near-term regulatory focus, but it does not grant approval. The FDA will make a decision on approvability once it has evaluated the full application.
Financing has become a more prominent concern for investors. As of June 30, preliminary cash, equivalents, and securities stood near $57 million. The company’s secured notes mandate a minimum liquidity of $40 million, tested monthly.
This results in a basic $17 million buffer. The $5 million payment due from Chiesi would increase this to $22 million, not accounting for new expenses. In the first quarter, $38.7 million in cash was consumed by operations. The pro forma buffer amounts to about 57% of that figure.
| Capital measure | Figure | Comparison |
|---|---|---|
| Estimated liquidity assets as of June 30 | ~$57 million | Company’s unaudited estimate |
| Chiesi payment under contract | $5 million | Basic pro forma aggregate: ~$62 million |
| Monthly liquidity requirement | $40 million | Basic pro forma surplus: ~$22 million |
| First-quarter cash used in operations | $38.7 million | Surplus represents around 57% |
| Equity inflow required to reach $20 million minimum | At least $100 million | First step down in covenant |
| Total equity inflow needed for zero minimum | At least $150 million | Earlier conditions must be satisfied |
These comparisons are straightforward and do not represent company guidance. They do not serve as a formal covenant computation. The cash amount as of June is still preliminary.
The covenant ladder includes an equity provision. The floor drops to $20 million once there are at least $100 million in equity proceeds. If FDA filing is accepted by December 1, the floor may fall further to $10 million. Should cumulative equity proceeds reach $150 million, the floor can be eliminated entirely.
The June debt swap altered the per-share calculation. Gossamer distributed 254.2 million ordinary shares and 33.4 million prefunded warrants. Additionally, it granted 135.8 million purchase warrants and $65.2 million in new convertible notes.
If fully converted at the initial rate, the notes would equal approximately 348.5 million shares. The conversion price set is about $0.19, close to Monday’s closing price. There is no guarantee that noteholders will convert or exercise warrants.
The updated deal with Chiesi gives Gossamer a larger share of sales economics. The previous 50/50 profit split for the U.S. ends, while rights outside the U.S. revert to Gossamer. Royalty and milestone payments are still capped. Gossamer will also no longer share development costs.
Chief Executive Faheem Hasnain described the update as “a defining moment for Gossamer.” He confirmed the company plans to file in September. Leerink raised its rating to Outperform, maintaining a $1 price target. H.C. Wainwright reaffirmed its Buy rating and $2 target. Gossamer Bio
Monday saw renewed optimism after a sharp downturn in February. PROSERA delivered a 13.3-meter improvement in placebo-adjusted walking distance over 24 weeks, but did not achieve the predefined statistical goal, leading shares to plunge 80%. The study included 390 participants.
The stock dropped by 20% over the prior week, finishing at $0.170 on July 17 and reaching $0.136 by July 24. Monday’s session not only recouped those losses but went further.
Gossamer’s public calendar currently shows no scheduled events. As a result, focus in the coming week will be on continued momentum and the possibility of any financing announcements.
Risks are still clustered. The FDA may reject the submission or withhold approval. Accessing fresh capital could be expensive or out of reach. Gossamer states its prospects rest solely on seralutinib. A reverse split is anticipated in or shortly following the third quarter.
